Abstract: A low-oxygen system is directed to culturing a diverse microbiome and includes an anaerobic chamber and at least one microfluidic device removably inserted in the anaerobic chamber. The microfluidic device includes a first microchannel in which a first level of oxygen is maintained, and a second microchannel in which a second level of oxygen is maintained, the second level of oxygen having a greater oxygen concentration than the first level of oxygen. The microfluidic device further includes a membrane located at an interface region between the first microchannel and the second microchannel, the membrane further having a plurality of pores via which oxygen flows from the second microchannel to the first microchannel to form an oxygen gradient in the first microchannel. The system further includes a culture system provided in the first microchannel and including oxygen-sensitive anaerobic bacteria.

Abstract: A device for simulating a function of a tissue includes a first structure, a second structure, and a membrane. The first structure defines a first chamber. The first chamber includes a matrix disposed therein and an opened region. The second structure defines a second chamber. The membrane is located at an interface region between the first chamber and the second chamber. The membrane includes a first side facing toward the first chamber and a second side facing toward the second chamber. The membrane separates the first chamber from the second chamber.

Abstract: An injector module includes a housing, a reservoir, a superelastic needle, and an actuator. The reservoir is positioned in the housing and stores epinephrine therein. The superelastic needle is positioned within the housing in a retracted position and is fluidly coupled with the reservoir. The superelastic needle has a gauge between eighteen and twenty-five. The actuator is configured to apply an actuator force on the superelastic needle such that the superelastic needle is moved from the retracted position to an injecting position where a tip of the superelastic needle protrudes from the housing between about fifteen millimeters and about thirty-five millimeters.

Abstract: Described herein are heme-binding compositions and methods relating to their use, e.g. methods of treatment of, for example, sepsis and rhabdomyolysis.

Abstract: Systems and methods for producing and using a body having a first structure defining a first chamber, a second structure defining a second chamber, a membrane located at an interface region between the first chamber and the second chamber to separate the first chamber from the second chamber. The first chamber comprises a first permeable matrix disposed therein and the first permeable matrix comprises at least one or a plurality of lumens each extending therethrough, which is optionally lined with at least one layer of cells. The second chamber can comprise cells cultured therein. The systems and methods described herein can be used for various applications, including, e.g., growth and/or differentiation of primary cells, and/or simulation of a microenvironment in living tissues and/or organs (to model physiology or disease states, and/or to identify therapeutic agents). The systems and methods can also permit co-cultures of two or more different cell types.

Abstract: Disclosed herein are organ chips that can be individually used or integrated together to form different microphysiological systems, e.g., for use in cell culturing, drug screening, toxicity assays, personalized therapeutic treatment, scaffolding in tissue repair and/or replacement, and/or pharmacokinetic or pharmacodynamics studies.

Abstract: A physiologic sensor module includes at least one wearable sensor that is configured for wearing on a human body part and for measuring at least one biological signal. The module further includes at least one controller communicatively coupled to the wearable sensor and configured to receive the biological signal from the wearable sensor. The controller is further configured to process the biological signal in real-time, extract one or more clinical features from the biological signal, and based on the clinical features, determine detection of anaphylaxis.

Abstract: TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia.

Abstract: The technology described herein is directed to methods and devices that can be used to induce functional organ structures to form within an implantation device by implanting it in vivo within the body of a living animal, and allowing cells and tissues to impregnate the implantation device and establish normal microenvironmental architecture and tissue-tissue interfaces. Then the contained cells and tissues can be surgically removed intact and either transplanted into another animal or maintained ex vivo by perfusing it through one or more of the fluid channels with medium and/or gases necessary for cell survival.

Abstract: The invention described herein relates generally to methods, sensors, devices and kits for electrochemical detection of a target analyte in a sample. In certain aspects, the methods, sensors, devices and kits described herein can be used to detect low concentrations of at least one target analyte using small sample volumes. In some embodiments, methods, sensors and kits for detecting a microbe, microbe fragment or released endotoxin in a test sample, including bodily fluids such as blood and tissues of a subject, food, water, and environmental surfaces, are also provided herein.

Abstract: A microfluidic coagulation assessment device includes a plurality of microchannels, with a blood sample driven through the microchannels at a substantially constant flow rate. A controller is configured to, in combination with a timer and a pressure sensing device, determine a first pressure value (or flow value) at an initiation of flow, a first time (Tpg) at which a second pressure value is about twice the determined first pressure value, and a second time (Tpf) at which a third pressure value is about (1+e) times the determined first pressure value and establish a subject coagulation model predictive of channel occlusion therefrom.

Abstract: Described herein are heme-binding compositions and methods relating to their use, e.g. methods of treatment of, for example, sepsis and rhabdomyolysis.

Abstract: A microfluidic system includes a microfluidic device connected to a bubble trap device whereby fluid flowing to the microfluidic device passes through the bubble trap device to remove gas bubbles prior to entering the microfluidic device. The bubble trap can include a separation chamber and an exhaust chamber separated by a hydrophobic porous membrane and gas bubbles in the fluid entering the separation chamber pass through the hydrophobic porous membrane into the exhaust chamber while the fluid remains in the separation chamber. The bubble trap can be formed by bonding a first body portion to a first side of the hydrophobic porous membrane and bonding a second body portion to a second side of the hydrophobic porous membrane. The exhaust chamber can be connected to an elongated exhaust channel that limits the evaporation losses of the fluid through the hydrophobic porous membrane.

Abstract: A microfluidic device for determining a response of cells comprises a microchannel and a seeding channel. The microchannel is at least partially defined by a porous membrane having cells adhered thereto. The microchannel has a first cross-sectional area. The seeding channel delivers a working fluid to the cells within the microchannel. The seeding channel has a second cross-sectional area that is less than the first cross-sectional area such that a flow of the working fluid produces a substantially higher shear force within the seeding channel to inhibit the attachment of cells within the seeding channel. And when multiple seeding channels are used to deliver fluids to multiple microchannels that define an active cellular layer across the membrane, the seeding channels are spatially offset from each other such that fluid communication between the fluids occurs only at the active region via the membrane, not at the seeding channels.

Abstract: According to aspects of the present invention, a cartridge assembly for transporting fluid into or out of one or more fluidic devices includes a first layer and a second layer. The first layer includes a first surface. The first surface includes at least one partial channel disposed thereon. The second layer abuts the first surface, thereby forming a channel from the at least one partial channel. At least one of the first layer and the second layer is a resilient layer formed from a pliable material. At least one of the first layer and the second layer includes a via hole. The via hole is aligned with the channel to pass fluid thereto. The via hole is configured to pass fluid through the first layer or the second layer substantially perpendicularly to the channel. Embossments are also used to define aspects of a fluidic channel.

Abstract: The technology described herein is directed to methods and devices that can be used to induce functional organ structures to form within an implantation device by implanting it in vivo within the body of a living animal, and allowing cells and tissues to impregnate the implantation device and establish normal microenvironmental architecture and tissue-tissue interfaces. Then the contained cells and tissues can be surgically removed intact and either transplanted into another animal or maintained ex vivo by perfusing it through one or more of the fluid channels with medium and/or gases necessary for cell survival.

Abstract: Embodiments of various aspects described herein relate to methods and compositions for injecting and/or delivering high viscosity and/or high concentration active agent solutions. In some embodiments, the methods and compositions described herein can be used for subcutaneous administration.

Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.

Abstract: A method for micro-molding a polymeric membrane and including pouring a predetermined volume of curable polymer unto a micro-fabricated mold having a post array with pillars, and overlaying the polymer with a support substrate. A spacer, such as a rubber spacer, is placed in contact with the support substrate and a force is applied to an exposed side of the spacer to compress the support substrate and the polymer together. While applying the force, the polymer is cured on the mold for a predetermined time period and at a predetermined temperature to form a polymeric membrane having a pore array with a plurality of pores corresponding to the plurality of pillars of the post array. The polymeric membrane is removed from the support substrate.

Abstract: The invention provides compositions and methods for treating or imaging stenosis, stenotic lesions, occluded lumens, embolic phenomena or thrombotic disorders. The invention further provides compositions and methods for treating internal hemorrhage.